Potassium Ion

Potassium Ion

SCHEMBL6063239

O=C([O-])C=CCCCS(=O)(=O)O.[K+]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 1/20 0.30
CA1 P00915 1/20 0.52
CA9 Q16790 1/20 0.52
EPHX2 P34913 2/20 0.39
APP P05067 1/20 0.37
BBOX1 O75936 1/20 0.36
FABP3 P05413 3/20 0.32
PDE4A P27815 1/20 0.30
LMNA P02545 1/20 0.30
SLC6A6 P31641 1/20 0.30
CYP2C19 P33261 1/20 0.30
BLM P54132 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL5426057 0.88 CA1 (0.56) CA1CA9EPHX2APPBBOX1
SCHEMBL5425315 0.83 CA1 (0.50) CA1CA9EPHX2APPBBOX1
SCHEMBL1132709 0.79 EPHX2 (0.41) EPHX2APPPTGS1PDE4ALMNA
SCHEMBL5428688 0.73 CHRNB2 (0.42) EPHX2APP
Potassium Ion SCHEMBL31310537 0.72 CA1 (0.58) CA1CA9BBOX1FABP3
Potassium Ion SCHEMBL29597204 0.72 CA1 (0.58) CA1CA9BBOX1FABP3
Potassium Ion SCHEMBL29092260 0.71 FABP3 (0.60) CA1CA9FABP3
Potassium Ion SCHEMBL514903 0.71 APP (0.35) EPHX2APP
Potassium Ion SCHEMBL514904 0.71 APP (0.35) EPHX2APP
SCHEMBL18091441 0.70 EPHX2 (0.43) EPHX2APPPTGS1PDE4ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634666-B2 Methods for spore removal comprising a polysorbate surfactant and cationic antimicrobial mixture 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-04-25 US disclosed
US-20180369118-A1 METHODS FOR SPORE REMOVAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-12-27 US disclosed
US-20180362895-A1 METHODS FOR SPORE REMOVAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-12-20 US disclosed
WO-2017112567-A1 METHODS FOR SPORE REMOVAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-06-29 WO disclosed
WO-2017112565-A1 METHODS FOR SPORE REMOVAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-06-29 WO disclosed
US-7012048-B2 Composition and method for treating hair containing a cationic ampholytic polymer and an anionic benefit agent NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2006-03-14 US disclosed
US-20040224862-A1 Composition and method for treating hair containing a cationic ampholytic polymer and an anionic benefit agent AKZO NOBEL N.V. (NL) 2004-11-11 US disclosed
EP-1447075-A2 Composition and method for treating hair containing a cationic ampholytic polymer and an anionic benefit agent National Starch and Chemical Investment Holding Corporation (US) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224862-A1 Composition and method for treating hair containing a cationic ampholytic polymer and an anionic benefit agent KRT18, PSAP, AREG PTGS1 3504/4885CA1 79/4885CA9 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.